Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Recruiting 31Active not recruiting 14Not yet recruiting 8Completed 5Terminated 3Withdrawn 2Unknown 2Enrolling by invitation 1Approved for marketing 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3Genitourinary 2Tumor-Agnostic 1Thoracic 1Gynecologic 1

Conditions

Triple Negative Breast Neoplasms 3Ovarian Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

Trastuzumab 87Cyclophosphamide 67Capecitabine 67Paclitaxel 64Docetaxel 58Fulvestrant 52Letrozole 50Carboplatin 42pembrolizumab 41Lapatinib 38Doxorubicin 36Anastrozole 32Vinorelbine 31Bevacizumab 31exemestane 28Tamoxifen 25Gemcitabine 25Albumin-Bound Paclitaxel 25Radiotherapy 21Taxes 19atezolizumab 18pertuzumab 17Everolimus 17130-nm albumin-bound paclitaxel 17Epirubicin 16palbociclib 15Magnetic Resonance Spectroscopy 15eribulin 14Ado-Trastuzumab Emtansine 14Goserelin 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × sacituzumab govitecan × Breast × Clear all
NCT04958785 2025-11-04

ELEVATE TNBC

Gilead Sciences

Phase 2 Terminated
92 enrolled 27 charts
Breast

Triple Negative Breast Neoplasms

NCT05113966 2025-01-29

Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer

G1 Therapeutics, Inc.

Phase 2 Terminated
30 enrolled 16 charts
Breast

Triple Negative Breast Neoplasms

NCT03992131 2024-01-16

A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)

pharmaand GmbH

Phase 1/2 Terminated
25 enrolled 11 charts
BreastGenitourinaryGynecologic

Carcinoma, Transitional Cell, Ovarian Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡